MEDI 0700

Drug Profile

MEDI 0700

Alternative Names: AMG 570; Anti-B7RP-1mAb/BAFF; MEDI0700

Latest Information Update: 10 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Amgen
  • Class Anti-inflammatories; Bispecific antibodies; Peptides; Recombinant proteins
  • Mechanism of Action B cell activating factor inhibitors; B7-related protein 1 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Rheumatoid arthritis; Systemic lupus erythematosus

Most Recent Events

  • 13 Jun 2018 Pharmacodynamics data from preclinical trials presented at 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 13 Jun 2018 Adverse events, pharmacokinetics and pharmacodynamics data from a phase I study in Healthy volunteers presented at the 19th Annual Congress of the European League Against Rheumatism (EULAR-2018)
  • 17 Apr 2018 AstraZeneca and Viela Bio enter into third party service agreement for the development of MEDI 0700 for Systemic lupus erythematous before April 2018 (Viela Bio pipeline, April 2018)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top